Emerging Strategies to Optimize Therapeutic Benefit in Advanced Gastrointestinal and Lung Cancers

Join oncology experts as they review the top presentations from ASCO in the lung and GI malignancy landscape. Discussions will include optimizations of advanced care practices.

Thank you for your interest in attending the Clinical Care Options (CCO) symposium, “Emerging Strategies to Optimize Therapeutic Benefit in Advanced Gastrointestinal and Lung Cancers” that was originally scheduled as an in-person symposium in Chicago, Illinois. Due to the global impact of COVID-19, ASCO organizers have decided to host the ASCO Annual Meeting in a virtual format.

As such, this live symposium will also now be held as a virtual live Webinar. Please note that each Webinar will still feature the original expert faculty, interactivity, evidence-based content, and panel discussions as the in-person symposium. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services

Agenda

Most Promising New Therapies for Advanced Lung and GI Malignancies (Faculty will highlight recent changes or new data in advanced lung and GI cancers that have the potential to significantly affect clinical practice)

  • Lung
    • NSCLC
    • SCLC
    • Mesothelioma
  • Noncolorectal GI cancers
    • Pancreatic
    • Gastric and gastroesophageal
    • Hepatobiliary
  • Metastatic colorectal cancer

Case Challenges: Integrating New Therapies Into Clinical Practice for Individual Patients

Panel Discussion: Best Practices for Collaborative Clinical Decision-Making and Optimizing Therapy Selection and Supportive Care to Maximize Clinical Benefit

  • Mitigating disease-related adverse events and the use of palliative and supportive care to improve therapy adherence and optimize survival
    • Palliative care: when to initiate and how it can support anticancer therapy
      • Improvements in quality of life
      • Reduced depression
      • Survival benefits
    • Early recognition and management of cancer-related anorexia and cachexia
      • Definition and Fearon criteria
      • Impact of cachexia on clinical outcomes
    • Available and emerging therapies
      • Ghrelin mimetics (anamorelin)
        • Data in lung cancer
        • Ongoing clinical trials in GI malignancies
      • Progesterone derivatives
      • Cannabinoids
      • Other therapeutic interventions

Events

Date / Time
Event Details

Faculty

Faculty
Mary Jo Fidler, MD

Faculty
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Program Overview
The primary purpose of this program is to equip clinicians with the tools to address real-world challenges in the management of lung and GI cancers.

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to apply the latest treatment approaches toward the optimal care of patients with advanced gastrointestinal and lung cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with advanced lung and gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate new and emerging practice-changing therapeutic strategies into the care of patients with advanced gastrointestinal and lung malignancies to optimize clinical outcomes
  • Implement palliative care measures in concert with anticancer therapies to improve quality of live and survival in patients with advanced GI and lung malignancies
  • Proactively manage cancer-related anorexia and cachexia in patients with advanced GI and lung cancers to enable patients to receive maximal benefit from anticancer therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.